GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biora Therapeutics Inc (OTCPK:BIOR) » Definitions » Ending Cash Position

BIOR (Biora Therapeutics) Ending Cash Position : $3.20 Mil (As of Sep. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Biora Therapeutics Ending Cash Position?

Biora Therapeutics's Ending Cash Position for the quarter that ended in Sep. 2024 was $3.20 Mil.

Biora Therapeutics's quarterly Ending Cash Position declined from Mar. 2024 ($10.82 Mil) to Jun. 2024 ($5.33 Mil) and declined from Jun. 2024 ($5.33 Mil) to Sep. 2024 ($3.20 Mil).

Biora Therapeutics's annual Ending Cash Position declined from Dec. 2021 ($88.40 Mil) to Dec. 2022 ($30.49 Mil) and declined from Dec. 2022 ($30.49 Mil) to Dec. 2023 ($15.21 Mil).

Biora Therapeutics Ending Cash Position Historical Data

The historical data trend for Biora Therapeutics's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biora Therapeutics Ending Cash Position Chart

Biora Therapeutics Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Ending Cash Position
Get a 7-Day Free Trial 33.04 92.08 88.40 30.49 15.21

Biora Therapeutics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 12.57 15.21 10.82 5.33 3.20

Biora Therapeutics Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Biora Therapeutics's Ending Cash Position for the fiscal year that ended in Dec. 2023 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=30.486+-15.275
=15.21

Biora Therapeutics's Ending Cash Position for the quarter that ended in Sep. 2024 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=5.325+-2.129
=3.20

Biora Therapeutics Ending Cash Position Related Terms

Thank you for viewing the detailed overview of Biora Therapeutics's Ending Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

Biora Therapeutics Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biora Therapeutics Inc (OTCPK:BIOR) » Definitions » Ending Cash Position
Comparable Companies
TIL AGLE CASI COYA DYAI IPA CRVO ASMB LGVN MTNB OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
4ZU:Germany
Address
4330 La Jolla Village Drive, Suite 300, San Diego, CA, USA, 92122
Website
https://www.bioratherapeutics.com
Biora Therapeutics Inc is a biotechnology company engaged in developing oral biotherapeutics. Its drug-device combinations could enable new treatment approaches in the delivery of therapeutics in two main areas: Targeted delivery of therapeutics to the site of disease in the gastrointestinal ("GI") tract, which is designed to improve outcomes for patients with Inflammatory Bowel Disease (IBD); and Systemic delivery of biotherapeutics, which are designed to replace injection with needle-free, oral delivery technology.
Executives
Athyrium Opportunities Iii Co-invest 1 Lp 10 percent owner 505 FIFTH AVENUE, FLOOR 18, NEW YORK NY 10017
Surbhi Sarna director ONE PENUMBRA PLACE, ALAMEDA CA 94502
Aditya P. Mohanty director, officer: Chief Executive Officer 1010 ATLANTIC AVENUE, SUITE 102, ALAMEDA CA 94501
Jill Ann Howe director C/O DTX PHARMA, INC., 10655 SORRENTO VALLEY ROAD, SUITE 100, SAN DIEGO CA 92121
Athyrium Capital Management, Lp 10 percent owner 505 FIFTH AVENUE, FLOOR 18, NEW YORK NY 10017
Athyrium Opportunities Fund (a) Lp 10 percent owner 605 THIRD AVENUE, 22ND FLOOR, NEW YORK NY 10158
Hutan Hashemi officer: Chief Compliance Officer 4330 LA JOLLA VILLAGE DRIVE, SUITE 200, SAN DIEGO CA 92122
Damon Silvestry officer: Chief Operating Officer 4330 LA JOLLA VILLAGE DRIVE, SUITE 200, SAN DIEGO CA 92122
Jeffrey D. Alter director 4330 LA JOLLA VILLAGE DRIVE, SUITE 200, SAN DIEGO CA 92122
Athyrium Opportunities Iii Acquisition Lp 10 percent owner 505 FIFTH AVENUE, 18TH FLOOR, NEW YORK NY 10017
Harry Stylli director, officer: Chairman & CEO 3595 JOHN HOPKINS CT, SAN DIEGO CA 92121
Matthew T Cooper officer: Chief Scientific Officer 4330 LA JOLLA VILLAGE DRIVE, SUITE 200, SAN DIEGO CA 92122
Athyrium Opportunities Advisers Llc 10 percent owner 1209 AVENUE OF THE AMERICAS, NEW YORK NY 10104
Athyrium Opportunities Associates Gp Llc 10 percent owner 1209 AVENUE OF THE AMERICAS, NEW YORK NY 10104
Athyrium Opportunities Associates Lp 10 percent owner 1209 AVENUE OF THE AMERICAS, NEW YORK NY 10104